Acevedo, M. L., Teoh, D., Adams, D., Nixon, A., Jingquan, J., Grace, L., … Alvarez-Secord, A. (2012). Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in leiomyosarcoma cell lines. In Gynecologic Oncology (Vol. 125, pp. S137–S137). Elsevier BV. https://doi.org/10.1016/j.ygyno.2011.12.334

Acevedo, M Lopez, D. Teoh, D. Adams, A. Nixon, J. Jingquan, L. Grace, R. Whitaker, and A. Alvarez-Secord. “Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in leiomyosarcoma cell lines.” In Gynecologic Oncology, 125:S137–S137. Elsevier BV, 2012. https://doi.org/10.1016/j.ygyno.2011.12.334.

Acevedo ML, Teoh D, Adams D, Nixon A, Jingquan J, Grace L, et al. Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in leiomyosarcoma cell lines. In: Gynecologic Oncology. Elsevier BV; 2012. p. S137–S137.

Acevedo, M. Lopez, et al. “Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in leiomyosarcoma cell lines.” Gynecologic Oncology, vol. 125, Elsevier BV, 2012, pp. S137–S137. Crossref, doi:10.1016/j.ygyno.2011.12.334.

Acevedo ML, Teoh D, Adams D, Nixon A, Jingquan J, Grace L, Whitaker R, Alvarez-Secord A. Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in leiomyosarcoma cell lines. Gynecologic Oncology. Elsevier BV; 2012. p. S137–S137.